[Effects of olprinone hydrochloride in patients undergoing off-pump coronary artery bypass grafting].
BACKGROUND
Olprinone hydrochloride (OLP) is a new phosphodiesterase III inhibitor with positive inotropic and vasodilator properties. It is characterized by strong inotropic effect and relatively weak vasodilating effect. Although the method for administration of OLP has been reasonably optimized, no studies have examined the administration mode for patients with off-pump coronary artery bypass grafting (OPCAB).


METHODS
After the start of the operation, 12 patients received OLP 0.2 microg x kg(-1) x min(-1) (OLP group) and 14 patients received normal saline (control group). Catecholamines were concomitantly administered to maintain systolic pressure > or = 100 mmHg and cardiac index (CI) > or = 2.5 l x min(-1) x m(-2). Hemodymanic parameters were measured after induction of anesthesia, at the administration of heparin, immediately after coronary artery anastomosis, at the end of the operation, and 3 h and 6 h after the operation.


RESULTS
Systolic and mean arterial pressures did not differ between the two groups. CI was significantly increased, and SVRI was significantly decreased after administration of heparin, immediately after coronary artery anastomosis, at the end of the operation and 3 h after the operation in the OLP group. OLP reduced the number of patients requiring dopamine and dobutamine compared with the control group.


CONCLUSIONS
The study showed that OLP administrated during OPCAB may have improved hemodynamics in patients for OPCAB.
Arai
Takero
T
Department of Anesthesiology, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya 343-8555.
Kamishima
Keiichiro
K
Terauchi
Tomoya
T
Enomoto
Yoshiro
Y
Shimazaki
Mutsuhisa
M
Inoue
Hisashi
H
Okuda
Yasuhisa
Y
D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D047549:Coronary Artery Bypass, Off-Pump; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology*
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011728:Pyridones; C059498:olprinone